AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9743816
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 3 x 400 mg/day
Trial: 3382159
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g I.V. as a single injection performed 1 hour before ESWL
Trial: 29911435
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) therapy recommendations
Trial: 29911435
Drug: Medication administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication administration record (MAR) recommendations
Trial: 18652326
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at Jingming (BL 1), Taiyang (EX‐HN 5), Chengqi (ST 1), Hegu (LI4)
Trial: 18652326
Drug: Eye drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drug treatment with local dropping of Aiweiduo
Trial: 18652326
Drug: Eye drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drug treatment
Trial: 16409197
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at maintenance doses of 20, 2,000, and 20,000 SQ‐U weekly for 1 year.
Trial: 16409197
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at higher doses (2,000 and 20,000 SQ‐U).
Trial: 15199077
Drug: DRF-1042 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRF-1042 at 120 mg/m(2)/day
Trial: 15199077
Drug: DRF-1042 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRF-1042 at 1.5 to 270 mg/m(2)
Trial: 7930386
Drug: Clomipramine 50
RxNorm normalized name: clomiPRAMINE 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 50 mg orally 2 hours before blood collection
Trial: 3286384
Drug: famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h
Trial: 3286384
Drug: famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 10 mg bolus injection iv followed by continuous infusions of 4 mg/h
Trial: 19140646
Drug: Working memory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Working memory training (twice weekly for 3 months)
Trial: 16766587
Drug: TAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC with primary prophylactic G-CSF (PPG)
Trial: 10404768
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives or hormone replacement therapy
Trial: 2672868
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine (30 mg)
Trial: 333601
Drug: Parenteral cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral cefazolin begun before operation
Trial: 333601
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic present in the tissues at the time of inoculation or resistant bacteria
Trial: 28720980
Drug: Cognitive Rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Rehabilitation Therapy (CRT)
Trial: 26200164
Drug: Xenograft (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenograft (1 g) + porous titanium (1 g) granules (Natix; Tigran Technologies AB)
Trial: 21987227
Drug: Modular cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular cognitive behavioral therapy (CBT)
Trial: 20151520
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous analgesia
Trial: 17164979
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol cocoa (329 mg flavanols, 61 mg epicatechin per 100 ml)
Trial: 17164979
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol cocoa (27 mg flavanols, 6.6 mg epicatechin per 100 ml)
Trial: 22317387
Drug: Improved land
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved land preparation tools (clod breaker, improved plough/'danella')
Trial: 22317387
Drug: Improved land
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved land preparation tools
Trial: 19172341
Drug: Ribonuclease-enriched lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribonuclease-enriched lactoferrin (R-ELF) supplement
Trial: 11848031
Drug: Immunotherapy using
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy using allogenic leukocytes from the partner
Trial: 9394162
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glucose, amino acids, and emulsion enriched in essential fatty acids (EFAs)
Trial: 25692479
Drug: cpTi implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cpTi implants
Trial: 25692479
Drug: TiZr and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiZr and cpTi implants
Trial: 24971004
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks
Trial: 24971004
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks in comorbid insomnia subgroup
Trial: 23060506
Drug: no vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no vaccine
Trial: 18668682
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 10 weeks
Trial: 18668682
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg twice daily for 10 weeks
Trial: 15129926
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d of supplemental calcium
Trial: 11794170
Drug: Additional localized
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional localized dose of 16 Gy radiation (given in eight fractions by external electron beam)
Trial: 11794170
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (50 Gy radiation to the whole breast)
Trial: 11794170
Drug: Additional localized
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional localized dose of 16 Gy radiation (for patients 40 years old or younger)
Trial: 11794170
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (for patients 40 years old or younger)
Trial: 11794170
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (for patients aged 41 to 50 years)
Trial: 29614276
Drug: 1-dose misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-dose misoprostol
Trial: 29614276
Drug: multiple-dose misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple-dose misoprostol
Trial: 27450392
Drug: Valaciclovir (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (2 g QDS or reduced according to renal function) for 6 months
Trial: 27450392
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment for 6 months
Trial: 23764238
Drug: 200mg TSU-68
RxNorm normalized name: TSUGA CANADENSIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg TSU-68 twice daily
Trial: 10396718
Drug: 10-ml 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-ml 0.125% bupivacaine administered twice daily for 4 days
Trial: 10396718
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered twice daily for 4 days
Trial: 10396718
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received treatment
Trial: 10396718
Drug: 10-ml 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-ml 0.125% bupivacaine administered
Trial: 2328177
Drug: Tubocurarine 0.4‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 0.4‐0.5 mg kg‐1
Trial: 2328177
Drug: Pancuronium 0.07‐0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.07‐0.08 mg kg‐1
Trial: 2328177
Drug: Alcuronium 0.2‐0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.2‐0.3 mg kg‐1
Trial: 30371552
Drug: Pure unilateral
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure unilateral rhythmic movement therapy consisting of 12 sessions over 1 month, involving straight or circular rhythmic movements with robotic assistance.
Trial: 23481119
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (leuprolide)
Trial: 11491421
Drug: Amprenavir 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir 900 mg twice daily
Trial: 11491421
Drug: Amprenavir 1050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir 1050 mg twice daily
Trial: 11491421
Drug: Amprenavir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir 1200 mg twice daily
Trial: 11491421
Drug: Amprenavir/Abacavir 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir/Abacavir 900 mg twice daily (combination therapy)
Trial: 9536859
Drug: beta-carotene (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-carotene (40 mg)
Trial: 9536859
Drug: lycopene (38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lycopene (38 mg)
Trial: 9536859
Drug: lutein (31.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lutein (31.2 mg)
Trial: 7625111
Drug: Oral RRV-TV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral RRV-TV rotavirus vaccine with IPV
Trial: 7625111
Drug: Oral RRV-TV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral RRV-TV rotavirus vaccine with OPV
Trial: 2773899
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (BSS) 30 ml (525 mg) q.i.d. for 21 days
Trial: 152612
Drug: 1% 6‐aminonicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% 6‐aminonicotinamide (6‐AN) gel
Trial: 152612
Drug: Topical 6‐AN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 6‐AN and oral niacinamide therapy
Trial: 152612
Drug: Topical 6‐AN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 6‐AN
Trial: 29587297
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy
Trial: 22959905
Drug: DMPA-SC (104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA-SC (104 mg administered at baseline and 12 weeks later)
Trial: 20625123
Drug: Methylphenidate (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (54 mg/d)
Trial: 18581018
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg of rocuronium
Trial: 10595696
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg once daily (o.d.)
Trial: 7113312
Drug: Profenid (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profenid (3 capsules + 1 suppositorium)
Trial: 7113312
Drug: Indomethacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (3 capsules + 1 suppositorium)
Trial: 30962094
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis vaccine IXIARO®
Trial: 30962094
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis vaccine IXIARO® with TBE vaccination
Trial: 30962094
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis vaccine IXIARO® without TBE vaccination
Trial: 28533517
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vortioxetine for 14 days
Trial: 22175765
Drug: Specific IgE
RxNorm normalized name: BSA specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgE ≥0.35 kU(A)/l for hazelnut
Trial: 22175765
Drug: Specific IgE
RxNorm normalized name: BSA specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgE cutoff of 26 kU(A)/l
Trial: 20179669
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g per day) plus dietary treatment
Trial: 17920338
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg 3 times a day for 6 weeks
Trial: 15704047
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Trial: 12842242
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg once daily
Trial: 12842242
Drug: Eplerenone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 200 mg once daily
Trial: 8885731
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (5 mg orally, every 4 hours)
Trial: 28070770
Drug: Immediate dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate dance intervention (10 private weekly dance lessons and 2 practice parties over 12 weeks)
Trial: 12597061
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg once daily, subcutaneous, starting postoperatively)
Trial: 8913184
Drug: Medical antireflux
RxNorm normalized name: VALVE,ANTIREFLUX UROCARE #6001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical antireflux therapy (ranitidine plus cisapride)
Trial: 1991415
Drug: 7.5 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 percent semisolid gel
Trial: 6856646
Drug: Procaine (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine (48 mg, 96 mg)
Trial: 29578090
Drug: Adjunctive internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive internet cognitive‐behavioral therapy
Trial: 29578090
Drug: Adjunctive internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive internet education
Trial: 27488327
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (300,000 IU intramuscular)
Trial: 27488327
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 mL as placebo)
Trial: 23791016
Drug: Structured withdrawal
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days)
Trial: 24308282
Drug: Tailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored intervention including training on medication management, provision of evidence-based checklists, a tablet PC with an interactive educational tool, and information leaflets for patients.
Trial: 18832497
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (second-generation antidepressants)
Trial: 16877896
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics (haloperidol 10 or 20 mg/day, perphenazine mean dose 28 mg/day, zuclopenthixol mean dose 38 mg/day)
Trial: 12512025
Drug: EP-1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EP-1 antagonist ZD6416
Trial: 3864167
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion therapy (100 micrograms/day, 3-hour intravenous infusion for three weeks)
Trial: 30430724
Drug: Single 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-g oral dose of TXA 2 h preoperatively followed by 1 g of oral TXA 3 h postoperatively (group B)
Trial: 30430724
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose followed by 1 g of oral TXA 3 h and 7 h postoperatively (group C)
Trial: 30430724
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose followed by 1 g of oral TXA 3 h, 7 h and 11 h postoperatively (group D)
Trial: 30430724
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose followed by 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively (group E)
Trial: 22833405
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived mononucleated cells (BM-MNC)
Trial: 18541126
Drug: NSPN extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSPN extract (360 mg Nigella sativa and 50 mg Phyllanthus niruri), administered 3 times daily for 7 days
Trial: 10937982
Drug: Candoxatril 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 200 mg b.d. (n = 22)
Trial: 10937982
Drug: Captopril 25-50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25-50 mg b.d. (n = 23)
Trial: 3315295
Drug: Transcutaneous cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous cardiac pacing (PACE) in addition to standard advanced cardiac life support (ACLS) treatment
Trial: 16714186
Drug: Adjuvanted 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 30 microg formulation
Trial: 11343051
Drug: Vinblastine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (6 mg/m², given intravenously every week)
Trial: 11343051
Drug: Etoposide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (150 mg/m²/d, given intravenously for 3 days every 3 weeks)
Trial: 7664216
Drug: lisinopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (ACE inhibitor)
Trial: 7664216
Drug: losartan (Ang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (Ang II receptor antagonist)
Trial: 7664216
Drug: hydrochlorothiazide (thiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (thiazide diuretic)
Trial: 2570004
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg terfenadine three times daily
Trial: 1071694
Drug: Chlorothiazide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (0.5 g twice daily)
Trial: 1071694
Drug: Metolazone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone (5 mg daily)
Trial: 23971894
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid misuse
Trial: 23465653
Drug: Metoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (5 mg IV over 5 min on commencement of bypass then 5 mg IV qid for 24h then 25-50 mg tds orally until discharge)
Trial: 23465653
Drug: Combined metoprolol
RxNorm normalized name: metoprolol and thiazides, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metoprolol and amiodarone (300 mg over 1h starting shortly after the commencement of bypass, then 900 mg over 24h then 400 mg orally tds until discharge)
Trial: 18813410
Drug: Injection plus
RxNorm normalized name: Bimectin Plus Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection plus physiotherapy
Trial: 18813410
Drug: Brace injection
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace injection
Trial: 16368830
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine infusion (500 microg bolus before anesthesia induction, followed by 125 microg/h until end of surgery)